CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −53 | $256.29 | $14K | 14,465 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −26 | $257.51 | $7K | 14,439 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −33 | $258.07 | $9K | 14,406 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −12 | $259.72 | $3K | 14,394 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −21 | $260.57 | $5K | 14,373 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −26 | $261.45 | $7K | 14,347 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −12 | $263.33 | $3K | 14,335 |
| 2025-02-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −14 | $264.87 | $4K | 14,321 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −349 | $252.50 | $88K | 14,749 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −386 | $253.37 | $98K | 14,363 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −258 | $254.35 | $66K | 14,105 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −110 | $255.56 | $28K | 13,995 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −126 | $256.29 | $32K | 13,869 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −60 | $257.51 | $15K | 13,809 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −77 | $258.07 | $20K | 13,732 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −27 | $259.72 | $7K | 13,705 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −49 | $260.57 | $13K | 13,656 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −60 | $261.45 | $16K | 13,596 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −27 | $263.33 | $7K | 13,569 |
| 2025-02-14 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −32 | $264.87 | $8K | 13,537 |
Page 38 of 41 · 816 trades